[Ip-health] Joint Statement: EU trade secrets directive threat to free speech, health, environment and worker mobility

Tessel Mellema Tessel at haiweb.org
Tue Mar 24 02:26:15 PDT 2015


23 March, 2015 (updated from 17 December, 2014)

EU trade secrets directive threat to free speech, health, environment and worker mobility

Multi-sectoral civil society coalition calls for greater protections for consumers, journalists, whistleblowers, researchers and workers

We strongly oppose the hasty push by the European Commission and Council for a new European Union (EU) directive on trade secrets because it contains:

·         An unreasonably broad definition of “trade secrets” that enables almost anything within a company to be deemed as such;

·         Far-reaching legal remedies for companies whose “trade secrets” have been “unlawfully acquired, used or disclosed”, including provisional and precautionary measures, damages and secrecy rights throughout the judicial process; and

·         Inadequate safeguards that will not ensure that EU consumers, journalists, whistleblowers, researchers and workers have reliable access to important data that is in the public interest.

The proposal must be amended to ensure that only information acquired, disclosed or used by third parties with intention of commercial gain is protected under the directive.

Specifically, we share great concern that under the draft directive:

·         The right to freedom of expression and information could be seriously harmed because the proposed directive does not guarantee the protection of journalists and whistleblowers. Under the proposed directive, journalists and whistleblowers must show that “...the alleged acquisition, use or disclosure of the trade secret was necessary for such revelation and that the respondent acted in the public interest”. Unfortunately, determining whether disclosure was necessary can often only be evaluated afterwards. In addition, the limitation of the right to disclose and use trade secrets to reveal “wrongdoing”, “misconduct” or to protect a “legitimate interest” would allow for sanctions to be applied even when the information ought to be in the public domain, such as planned redundancies and detrimental effects on health and the environment. The proposed directive should be amended to exempt information acquired, used or disclosed in the public interest.

·         The mobility of EU workers could be undermined. The proposed directive poses a danger of lock-in effects for workers. It could create situations where an employee will avoid jobs in the same field as his/her former employer, rather than risking not being able to use his/her own skills and competences, and being liable for damages. This inhibits career development, as well as professional and geographical mobility in the labour market.

·         Companies in the health, environment and food safety fields might use the directive to refuse compliance with transparency policies, even when the public interest is at stake. The proposed directive should be amended to ensure that (1) it does not cover information that must, by law (including international law), be disclosed by public authorities under public access to information legislation and (2) it excludes regulatory data of public interest that is needed for public scrutiny of regulatory authorities’ activities.

Health: Pharmaceutical companies argue that all aspects of clinical development should be
considered a trade secret; however, access to biomedical research data by regulatory authorities, researchers, doctors and patients—particularly data on drug efficacy and adverse drug reactions—is critical to protecting patient safety and conducting further research and independent analyses. This information also prevents scarce public resources from being spent on therapies that are no better than existing treatments, do not work, or do more harm than good. Moreover, disclosure of pharmaceutical research is needed to avoid unethical repetition of clinical trials on people. The proposed directive should not obstruct recent EU developments to increase sharing and transparency of this data.

Environment: The directive must be amended to comply with the EU’s international obligations under the United Nations Aarhus Convention, which prevents public authorities from protecting the secrecy of information on emissions into the environment and requires active dissemination of information enabling consumers to make informed environmental choices. Therefore, the definition of “trade secret” should be amended to remove information on emissions from the scope of the proposed directive and companies should be prevented from using the directive to refuse disclosure of information on hazardous products, such as chemicals in plastics, clothing, cleaning products, and other activities that can cause severe damage to the environment and human health, including the dumping of chemicals and fracking fluids.

Food safety: Under EU law, all food products, genetically modified organisms and pesticides are assessed by the European Food Safety Authority (EFSA). EFSA assesses the risks associated with these products based on studies performed by manufacturers themselves. Scientific scrutiny of the EFSA's assessments is only possible with complete access to these studies; therefore, this data must be removed from the scope of the directive.

Despite the Commission’s desire for a “magic bullet” that will keep Europe in the innovation game, without amendment, the proposed directive may make it more difficult for the EU to engage in open and collaborative forms of research. In fact, there is a risk that the measures and remedies provided in this directive will undermine legitimate competition and even facilitate anti-competitive behaviour. Unsurprisingly, the text is strongly supported by multinational companies.

Industry coalitions in the EU and the United States (US) are lobbying, through a unified Trade Secrets Coalition, for the adoption of trade secret protection. In the US, two new bills are pending before Congress. If passed, these texts would allow trade secret protection to be included in the Transatlantic Trade and Investment Partnership (TTIP)—something that will be incredibly difficult to repeal in the future through democratic processes. Given that TTIP is expected to set a new global standard, its potential inclusion of trade secret protection could have devastating consequences.

We urge the Council and the European Parliament to amend the directive by limiting the definition of what constitutes a trade secret and strengthening safeguards and exceptions to ensure that data in the public interest cannot be protected as trade secrets. The right to freely use and disseminate information should be the rule, and trade secret protection the exception.

For additional information or comment, please contact:


Health Action International

Tessel Mellema, Policy Advisor / tessel at haieurope.org<mailto:tessel at haieurope.org> / +31 20 683 3684

Ancel.la Santos Quintano, Policy Advisor / ancel.la at haieurope.org<mailto:ancel.la at haieurope.org> / +31 20 683 3684


Medicines in Europe Forum

Pierre Chirac, Coordinator / pierrechirac at aol.com<mailto:pierrechirac at aol.com>


Commons Network

Sophie Bloemen, Coordinator / info at commonsnetwork.eu<mailto:info at commonsnetwork.eu>


Public Citizen, US

Burcu Kilic, Legal Counsel, Global Access to Medicines Program / bkilic at citizen.org<mailto:bkilic at citizen.org> /+1 202 588 1000


European Public Health Alliance
Kolia Bénié, EU Affairs and Governance Policy Coordinator / kolia at epha.org<mailto:kolia at epha.org> / +32 2 233 38 84

Knowledge Ecology International (KEI) Europe
Thiru Balasubramaniam, Staff Coordinator / thiru at keionline.org<mailto:thiru at keionline.org>

Cochrane Collaboration – Nordic Cochrane Centre

Peter Goetzsche, Director / pcg at cochrane.dk<mailto:pcg at cochrane.dk>


International Society of Drug Bulletins (ISDB)

press at isdbweb.org<mailto:press at isdbweb.org>


Association Internationale de la Mutualité (AIM)

Menno Aarnout, Executive Director / menno.aarnout at aim-mutual.org<mailto:menno.aarnout at aim-mutual.org>


Berne Declaration
Patrick Durisch, Responsable Programme Santé – Health Programme Coordinator  / durisch at ladb.ch<mailto:durisch at ladb.ch> /
+41 21 620 03 06

Health Projects for Latvia
Ieva Salmane-Kuļikovska, Chair of the Board / veselibasprojekti at gmail.com<mailto:veselibasprojekti at gmail.com>

HEAL (Health & Environment Alliance)

Génon K. Jensen, Executive Director / genon at env-health.org<mailto:genon at env-health.org> / +32 2 234 36 47



Corporate Europe Observatory (CEO)
Martin Pigeon, Researcher and Campaigner / martin at corporateeurope.org<mailto:martin at corporateeurope.org> / +32 2 89 30 930

GeneWatch UK

Helen Wallace, Director / helen.wallace at genewatch.org<mailto:helen.wallace at genewatch.org> / +44 (0)1298 24300


EFFAT (European Federation of Food, Agriculture, Tourism Trade Unions)
Harald Wiedenhofer, General Secretary/ H.wiedenhofer at effat.org/<mailto:H.wiedenhofer at effat.org/> + 32 2 209 62 63


Client Earth

Anaïs Berthier, Senior Lawyer/juriste - Environmental Justice / aberthier at clientearth.org<mailto:aberthier at clientearth.org> / +32 2 808 3468

Center for International Environmental Law (CIEL)
David Azoulay, Senior Attorney, Health and Environment Program Director / dazoulay at ciel.org<mailto:dazoulay at ciel.org>

Greenpeace (EU unit)

Andrea Carta, Legal Strategist - European Unit / andrea.carta at greenpeace.org<mailto:andrea.carta at greenpeace.org> / +32 2 274 1920


EEB (the European Environmental Bureau)

Jeremy Wates, Secretary General / jeremy.wates at eeb.org<mailto:jeremy.wates at eeb.org> / +32 (0) 2289 1091


NatureFriends International (NFI)

Seda Orhan Defranceschi, Head of Brussels Office / seda.orhan at nf-int.org<mailto:seda.orhan at nf-int.org>


Commons Network

Sophie Bloemen, Coordinator / info at commonsnetwork.eu<mailto:info at commonsnetwork.eu>



Centre national de coopération au développement (CNCD-11.11.11”)

Antonio Gambini, recherche et plaidoyer financement du développement / antonio.gambini at cncd.be<mailto:antonio.gambini at cncd.be> /
+32 (0) 2 613 30 31


TransAtlantic Consumer Dialogue (TACD)

David Hammerstein, Senior Policy Advocate, hammerstein.david3 at gmail.com<mailto:hammerstein.david3 at gmail.com>



French journalists collective “Informer n'est pas un délit”
informernestpasundelit at gmail.com<mailto:informernestpasundelit at gmail.com>


La Quadrature du Net
Marie Walrafen / contact at laquadrature.net<mailto:contact at laquadrature.net> / +33 (0)972 294 426

Corporate Europe Observatory (CEO)
Martin Pigeon, Researcher and Campaigner / martin at corporateeurope.org<mailto:martin at corporateeurope.org> / +32 2 89 30 930

Article 19

David Banisar, Senior Legal Counsel / banisar at article19.org<mailto:banisar at article19.org> / +44 20 7324 2500


Electronic Frontier Foundation (EFF)

Jeremy Malcolm, Senior Global Policy Analyst / jmalcolm at eff.org<mailto:jmalcolm at eff.org>


EDRi (European Digital Rights)

walter at vrijschrift.nl<mailto:walter at vrijschrift.nl>


The Foundation for Information Policy Research

Ross Anderson / Ross.Anderson at cl.cam.ac.uk<mailto:Ross.Anderson at cl.cam.ac.uk> / +44 1223 334733



walter at vrijschrift.nl<mailto:walter at vrijschrift.nl>


CEE Bankwatch Network

Petr Hlobil, Campaigns Director / petrh at bankwatch.org<mailto:petrh at bankwatch.org>  / +420 274 822 150

Transparency International France

Daniel Lebègue, Président / contact at transparency-france.org<mailto:contact at transparency-france.org> / +33 1 84 16 95 65


Fondation Sciences Citoyennes

Bertrand Bocquet, Président / contact at sciencescitoyennes.org<mailto:contact at sciencescitoyennes.org> / +33 1 43 14 73 65

EUROCADRES (Council of European Professional and Managerial Staff)
Martin Jefflén, President / martin.jefflen at eurocadres.eu<mailto:martin.jefflen at eurocadres.eu> / +32 473 555 344

EPSU (European Federation of Public Service Unions)
Jan Willem Goudriaan, General Secretary / jwgoudriaan at epsu.org<mailto:jwgoudriaan at epsu.org> / +32 2 250 10 90

ETUC (European Trade Union Confederation)
Legal Advisor, Séverine Picard / spicard at etuc.org<mailto:spicard at etuc.org> / +32 2 224 04 09

CFDT CADRES (CFDT for Professional and Managerial Staff)

Jean-Paul BOUCHET, secrétaire Général / jean-paul.bouchet at cadres.cfdt.fr<mailto:jean-paul.bouchet at cadres.cfdt.fr> / +33 1 56 41 55 00


Akademikerna (The Danish Confederation of Professional Associations)
Käthe Munk Ryom, International chief Advisor / kmr at ac.dk<mailto:kmr at ac.dk> / +45 2249 5866

AGENQUADRI (General Association of Managers, Professionals and High-Skilled Workers)
Paolo Terranova, President / p.terranova at cgil.it<mailto:p.terranova at cgil.it> / +39 06 8476336
Åsa Ehinger Berling, International Secretary / +46 70 6213230

UNI Europa
Christina Colclough, Head of EU Affairs / Christina.colclough at uniglobalunion.org<mailto:Christina.colclough at uniglobalunion.org> / +32 471936751
Akava (Confederation of Unions for Professional and Managerial Staff in Finland)
Jaana Meklin, Legal Adviser / jaana.meklin at akava.fi<mailto:jaana.meklin at akava.fi>

Ann-Heléne Westrup, International Secretary /ann-helene.westrup at unionen.se<mailto:ann-helene.westrup at unionen.se> / 46 8-504 155 17

TCO (Swedish Confederation of Professional Employees)
German Bender, Utredare/Senior Research Officer / +46-8-782 91 85

Tessel Mellema
Policy Advisor

Health Action International (HAI) Europe
Overtoom 60 (2)
1054 HK Amsterdam
The Netherlands
T: +31 (0) 20 683 3684
M: +31 (0) 6 24686771
E: tessel at haieurope.org<mailto:tessel at haieurope.org>


Health Action International (HAI) Europe is an independent network working to increase access to essential medicines and improve their rational use through research excellence and evidence-based advocacy.

More information about the Ip-health mailing list